Scientists successfully test MERS vaccine in monkeys and camels

21-Aug-2015 - USA

National Institutes of Health (NIH) scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels.

Led by NIH-funded University of Pennsylvania scientists, the research team developed the investigational MERS vaccine by learning from previous vaccine studies of another coronavirus that causes severe acute respiratory syndrome (SARS). SARS sickened more than 8,000 people and killed more than 700 in 2003. The experimental MERS vaccine uses the S spike protein to generate immunity; because MERS-CoV undergoes mutations, the scientists created a "consensus" S protein by comparing all available MERS-CoV protein sequences. This synthetic protein has shown broad protection against different MERS-CoV types, the scientists report. Collaborators included researchers from NIH's National Institute of Allergy and Infectious Diseases, Division of Intramural Research; Public Health Agency of Canada; Inovio Pharmaceuticals; the University of Washington; and the University of South Florida.

Original publication

K. Muthumani et al.; "A synthetic consensus anti-Spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates."; Science Translational Medicine; 2015

https://www.bionity.com/en/news/154192/scientists-successfully-test-mers-vaccine-in-monkeys-and-camels.html